Benzinga - Mon, 12 Apr 2021 12:00:14 -0400
Benzinga - Fri, 09 Apr 2021 05:04:24 -0400
Benzinga - Thu, 08 Apr 2021 12:01:05 -0400
Benzinga - Tue, 06 Apr 2021 10:55:37 -0400
load more
Sector: Health Care.Industry: Biotechnology
Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD.

Earnings

see more
Q1 2021Est.ActualSurprise
EPS
(EXPECTED)2021-06-25
REV
Q4 2020Est.ActualSurprise
EPS
(EXPECTED)2021-04-23
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
RXDXPrometheus Biosciences-17.94%

Prometheus Biosciences Company Questions & Answers

Q

How do I buy Prometheus Biosciences (RXDX) stock?

A

You can purchase shares of Prometheus Biosciences (NASDAQ: RXDX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Prometheus Biosciences's (RXDX) main competitors?

A

There are no as such competitors for Prometheus Biosciences.

Q

What is the target price for Prometheus Biosciences?

A

The latest price target for Prometheus Biosciences (NASDAQ: RXDX) was reported by Guggenheim on 2021-04-06. The analyst firm set a price target for 40.00 expecting RXDX to rise to within 12 months (a possible 112.77% upside). 4 analyst firms have reported ratings in the last year.

Q

How much is Prometheus Biosciences (RXDX) stock ?

A

The stock price for Prometheus Biosciences (NASDAQ: RXDX) is $18.8 last updated Mon Apr 12 2021 20:00:01 GMT+0000 (Coordinated Universal Time).

Q

When is the next Prometheus Biosciences (RXDX) dividend?

A

There are no upcoming dividends for Prometheus Biosciences.

Q

When is Prometheus Biosciences (NASDAQ:RXDX) reporting earnings?

A
Prometheus Biosciences’s Q1 earnings are confirmed after-market from now on June 25, 2021.
Q

When is the upcoming split for RXDX?

A

There is no upcoming split for Prometheus Biosciences.